| Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
|
Apr '12
|
Lord Glendonbrook
|
|
Astrazeneca / LSE:AZN.L |
£2,666.50
|
£13,694.00
|
413.56%
|
£359,489.97
|
|
Apr '10
|
Baroness Noakes
|
|
Astrazeneca / LSE:AZN.L |
£2,938.00
|
£13,694.00
|
366.10%
|
£326,269.57
|
|
Mar '14
|
Viscount Eccles
|
|
Astrazeneca / LSE:AZN.L |
£3,876.50
|
£13,694.00
|
253.26%
|
£247,279.76
|
|
Feb '11
|
Lord Wasserman
|
|
Johnson & Johnson / NYQ:JNJ |
£60.93
|
£205.33
|
236.99%
|
£235,895.29
|
|
Dec '16
|
Lord Burns
|
|
Astrazeneca / LSE:AZN.L |
£4,116.00
|
£13,694.00
|
232.70%
|
£232,891.16
|
|
Jan '13
|
Lord Sassoon
|
|
Johnson & Johnson / NYQ:JNJ |
£72.69
|
£205.33
|
182.47%
|
£197,731.46
|
|
May '18
|
Lord Grabiner
|
|
Astrazeneca / LSE:AZN.L |
£5,417.00
|
£13,694.00
|
152.80%
|
£176,957.73
|
|
May '11
|
Lord Glendonbrook
|
|
Novartis / NYQ:NVS |
£54.04
|
£133.72
|
147.44%
|
£173,208.53
|
|
Apr '17
|
Lord Donoughue
|
|
Novartis / NYQ:NVS |
£66.05
|
£133.72
|
102.46%
|
£141,720.35
|
|
Sep '16
|
Lord Gadhia
|
|
Astrazeneca / LSE:AZN.L |
£5,099.00
|
£10,024.00
|
96.59%
|
£137,611.30**
|
|
Feb '21
|
Lord Etherton
|
|
Astrazeneca / LSE:AZN.L |
£7,422.00
|
£13,694.00
|
84.51%
|
£129,153.87
|
|
Jun '21
|
Lord Morse
|
|
Astrazeneca / LSE:AZN.L |
£8,005.00
|
£13,694.00
|
71.07%
|
£119,747.66
|
|
Jul '16
|
Lord Lloyd-Webber
|
|
Johnson & Johnson / NYQ:JNJ |
£122.64
|
£205.33
|
67.42%
|
£117,197.49
|
|
Aug '14
|
Lord Carter of Coles
|
|
Johnson & Johnson / NYQ:JNJ |
£100.16
|
£161.55
|
61.29%
|
£112,904.35**
|
|
Nov '23
|
Lord Mance
|
|
Eli Lilly Co / VIE:LLYC.VI |
£557.00
|
£892.10
|
60.16%
|
£112,113.10
|
|
Apr '21
|
Baroness Deech
|
|
Novartis / NYQ:NVS |
£88.38
|
£133.72
|
51.30%
|
£105,910.84
|
|
May '24
|
Lord Goldsmith
|
|
Abbvie / NYQ:ABBV |
£160.81
|
£230.24
|
43.18%
|
£100,222.63
|
|
Apr '24
|
Lord Mendoza
|
|
Eli Lilly / NYQ:LLY |
£731.33
|
£1,033.56
|
41.33%
|
£98,928.26
|
|
May '20
|
Lord Deighton
|
|
Astrazeneca / LSE:AZN.L |
£8,361.00
|
£11,236.00
|
34.39%
|
£94,070.09**
|
|
Nov '23
|
Lord Mance
|
|
Astrazeneca / LSE:AZN.L |
£10,230.00
|
£13,694.00
|
33.86%
|
£93,702.83
|
|
May '25
|
Lord Hayward
|
|
Glaxosmithkline / NYQ:GSK |
£37.37
|
£48.97
|
31.04%
|
£91,728.66
|
|
Dec '16
|
Lord Burns
|
|
Glaxosmithkline / NYQ:GSK |
£37.39
|
£48.97
|
30.97%
|
£91,679.60
|
|
May '11
|
Lord Glendonbrook
|
|
Pfizer / NYQ:PFE |
£19.54
|
£25.57
|
30.83%
|
£91,580.32
|
|
Mar '25
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£161.72
|
£205.33
|
26.97%
|
£88,876.45
|
|
Jan '24
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£251.85
|
£313.80
|
24.60%
|
£87,218.58
|
|
May '23
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£165.03
|
£205.33
|
24.42%
|
£87,093.86
|
|
Apr '10
|
Lord Levene of Portsoken
|
|
Glaxosmithkline / NYQ:GSK |
£39.38
|
£48.97
|
24.35%
|
£87,046.72
|
|
Apr '10
|
Baroness Noakes
|
|
Glaxosmithkline / NYQ:GSK |
£39.49
|
£48.97
|
24.01%
|
£86,804.25
|
|
Apr '17
|
Lord Leigh of Hurley
|
|
Roche / EBS:ROG.SW |
£255.80
|
£313.80
|
22.67%
|
£85,871.77
|
|
Aug '17
|
Lord Sterling of Plaistow
|
|
Johnson & Johnson / NYQ:JNJ |
£133.45
|
£157.98
|
18.38%
|
£82,866.99**
|
|
May '23
|
Lord Fink
|
|
Astrazeneca / LSE:AZN.L |
£11,774.00
|
£13,694.00
|
16.31%
|
£81,414.98
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Glaxosmithkline / NYQ:GSK |
£42.31
|
£48.97
|
15.74%
|
£81,018.67
|
|
May '23
|
Lord Londesborough
|
|
Astrazeneca / LSE:AZN.L |
£11,924.00
|
£13,694.00
|
14.84%
|
£80,390.81
|
|
May '11
|
Lord Glendonbrook
|
|
Glaxosmithkline / NYQ:GSK |
£42.78
|
£48.97
|
14.47%
|
£80,128.57
|
|
Apr '24
|
Lord Balfe
|
|
Astrazeneca / LSE:AZN.L |
£12,024.00
|
£13,694.00
|
13.89%
|
£79,722.22
|
|
May '24
|
Lord Goldsmith
|
|
Astrazeneca / LSE:AZN.L |
£12,156.00
|
£13,694.00
|
12.65%
|
£78,856.53
|
|
Apr '23
|
Lord Grabiner
|
|
Novartis / NYQ:NVS |
£95.80
|
£107.52
|
12.23%
|
£78,563.67**
|
|
Apr '21
|
Lord Farmer
|
|
Glaxosmithkline / NYQ:GSK |
£36.65
|
£40.88
|
11.54%
|
£78,079.12**
|
|
May '24
|
Lord Balfe
|
|
Glaxosmithkline / NYQ:GSK |
£44.02
|
£48.97
|
11.24%
|
£77,871.42
|
|
Jan '13
|
Lord Sassoon
|
|
Glaxosmithkline / NYQ:GSK |
£44.75
|
£48.97
|
9.43%
|
£76,601.12
|
|
Oct '20
|
Lord Taverne
|
|
Glaxosmithkline / NYQ:GSK |
£37.57
|
£40.95
|
9.00%
|
£76,297.58**
|
|
May '23
|
Lord Leitch
|
|
Astrazeneca / LSE:AZN.L |
£11,820.00
|
£12,340.00
|
4.40%
|
£73,079.53**
|
|
Mar '25
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£303.00
|
£313.80
|
3.56%
|
£72,495.05
|
|
Nov '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£309.00
|
£313.80
|
1.55%
|
£71,087.38
|
|
Apr '21
|
Lord Grabiner
|
|
Roche / EBS:ROG.SW |
£309.65
|
£313.80
|
1.34%
|
£70,938.15
|
|
Feb '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£285.70
|
£272.40
|
-4.66%
|
£66,741.33**
|
|
Mar '14
|
Baroness Eccles of Moulton
|
|
Glaxosmithkline / NYQ:GSK |
£53.43
|
£48.97
|
-8.35%
|
£64,156.84
|
|
Feb '16
|
Lord Lloyd-Webber
|
|
Pfizer / NYQ:PFE |
£29.02
|
£25.57
|
-11.90%
|
£61,672.27
|
|
Jan '20
|
Lord Gadhia
|
|
Glaxosmithkline / NYQ:GSK |
£46.50
|
£40.95
|
-11.94%
|
£61,645.16**
|
|
Apr '22
|
Lord Cromwell
|
|
Johnson & Johnson / NYQ:JNJ |
£179.90
|
£154.37
|
-14.19%
|
£60,066.15**
|
|
May '23
|
Lord Reay
|
|
Sanofi / NMS:SNY |
£55.11
|
£47.22
|
-14.32%
|
£59,978.23**
|
|
Aug '16
|
Lord Lloyd-Webber
|
|
Eli Lilly / NYQ:LLY |
£80.55
|
£67.15
|
-16.64%
|
£58,355.06**
|
|
Aug '20
|
Lord Reay
|
|
Roche / EBS:ROG.SW |
£315.05
|
£249.80
|
-20.71%
|
£55,502.30**
|
|
Jul '18
|
Lord Glendonbrook
|
|
Bayer / GER:BAYN.DE |
£95.26
|
£34.25
|
-64.05%
|
£25,167.96
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.